A Phase 2 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-11.
Sponsored by Pfizer · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received Prevnar in study D118-P8
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects received MnCC in study D118-P8
Biological: 13-valent Pneumococcal Conjugate Vaccine
single injection, single dose, single site, 0.5 mL per dose.
Also known as: 13vPnC
single injection, single dose, single site, 0.5 mL per dose.
Also known as: 13vPnC
Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.
Time frame: Day 28 (Visit 5)
Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.
Time frame: Day 7 (Visit 4)
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
Time frame: Day 28 (Visit 5)
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
Time frame: Day 7 (Visit 4)
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.
Time frame: Day 28 (Visit 5)
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.
Time frame: Day 7 (Visit 4)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 28 (Visit 5)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 28 (Visit 5)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 7 (Visit 4)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 7 (Visit 4)
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 28 (Visit 5)
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 28 (Visit 5)
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 7 (Visit 4)
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Baseline (Visit 1), Day 7 (Visit 4)
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Day 28 (Visit 5)
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Day 7 (Visit 4)
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Day 28 (Visit 5)
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: Day 7 (Visit 4)
Percentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination
Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (\> 7.0 cm). Participants may be represented in \>1 category.
Time frame: Baseline up to 4 days after vaccination on Day 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination
Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), \>39 but ≤40 degrees C (moderate), or \>40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).
Time frame: Baseline up to 4 days after vaccination on Day 1
Participants were previously enrolled in Prevnar protocol D118-P8 (study duration 1995 to 1998) and were randomized to receive either 7-valent pneumococcal conjugate vaccine or meningococcal C conjugate vaccine in that study.
| Milestone | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| Started | 38 | 37 |
| Received vaccination 13vpnc | 38 | 36 |
| Completed | 38 | 36 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 6B | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 14 | 100.0 (90.7 to 100.0) | 97.1 (85.1 to 99.9) |
| 7vPnC serotype 18C | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 19F | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 23F | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 1 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 3 | 94.7 (82.3 to 99.4) | 97.0 (84.2 to 99.9) |
| Additional serotype 5 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 7F | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 19A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 94.7 (82.3 to 99.4) | 85.7 (69.7 to 95.2) |
| 7vPnC serotype 6B | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 97.1 (85.1 to 99.9) |
| 7vPnC serotype 14 | 100.0 (90.7 to 100.0) | 94.3 (80.8 to 99.3) |
| 7vPnC serotype 18C | 97.4 (86.2 to 99.9) | 94.3 (80.8 to 99.3) |
| 7vPnC serotype 19F | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 23F | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 1 | 100.0 (90.7 to 100.0) | 97.1 (85.1 to 99.9) |
| Additional serotype 3 | 94.7 (82.3 to 99.4) | 87.9 (71.8 to 96.6) |
| Additional serotype 5 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 7F | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 19A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 100.0 (90.3 to 100.0) | 100.0 (89.1 to 100.0) |
| 7vPnC serotype 6B | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 14 | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 18C | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 19F | 97.4 (86.2 to 99.9) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 23F | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 1 | 100.0 (90.7 to 100.0) | 97.1 (84.7 to 99.9) |
| Additional serotype 3 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 5 | 89.5 (75.2 to 97.1) | 88.6 (73.3 to 96.8) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| Additional serotype 7F | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 19A | 97.4 (86.2 to 99.9) | 100.0 (90.0 to 100.0) |
Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 97.4 (86.2 to 99.9) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 6B | 100.0 (90.7 to 100.0) | 100.0 (89.4 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 14 | 100.0 (90.5 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 18C | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 19F | 94.3 (80.8 to 99.3) | 97.1 (84.7 to 99.9) |
| 7vPnC serotype 23F | 97.3 (85.8 to 99.9) | 94.3 (80.8 to 99.3) |
| Additional serotype 1 | 100.0 (90.5 to 100.0) | 97.1 (85.1 to 99.9) |
| Additional serotype 3 | 97.4 (86.2 to 99.9) | 100.0 (89.7 to 100.0) |
| Additional serotype 5 | 89.5 (75.2 to 97.1) | 88.2 (72.5 to 96.7) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 7F | 100.0 (90.5 to 100.0) | 97.0 (84.2 to 99.9) |
| Additional serotype 19A | 97.4 (86.2 to 99.9) | 100.0 (90.0 to 100.0) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | 7vPnC / 13vPnC Prevaccination Visit 1 | 7vPnC / 13vPnC Postvaccination Visit 5 |
|---|---|---|
| 7vPnC serotype 4 | 0.20 (0.12 to 0.33) | 5.96 (4.10 to 8.65) |
| 7vPnC serotype 6B | 5.89 (4.61 to 7.51) | 66.72 (50.19 to 88.70) |
| 7vPnC serotype 9V | 1.54 (1.19 to 2.00) | 8.62 (6.55 to 11.34) |
| 7vPnC serotype 14 | 0.58 (0.39 to 0.86) | 41.45 (27.72 to 61.97) |
| 7vPnC serotype 18C | 0.75 (0.48 to 1.18) | 5.93 (4.34 to 8.11) |
| 7vPnC serotype 19F | 2.94 (2.08 to 4.15) | 13.41 (8.89 to 20.23) |
| 7vPnC serotype 23F | 2.51 (1.92 to 3.27) | 17.20 (12.44 to 23.77) |
| Additional serotype 1 | 1.04 (0.71 to 1.54) | 11.59 (7.34 to 18.30) |
| Additional serotype 3 | 1.30 (0.83 to 2.04) | 2.19 (1.60 to 2.99) |
| Additional serotype 5 | 3.24 (2.45 to 4.27) | 6.80 (4.75 to 9.74) |
| Additional serotype 6A | 3.78 (2.85 to 5.03) | 29.11 (19.04 to 44.50) |
| Additional serotype 7F | 1.38 (0.93 to 2.05) | 9.92 (7.03 to 14.01) |
| Additional serotype 19A | 7.05 (5.52 to 8.99) | 21.29 (14.90 to 30.43) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | MnCC / 13vPnC Prevaccination Visit 1 | MnCC / 13vPnC Postvaccination Visit 5 |
|---|---|---|
| 7vPnC serotype 4 | 0.15 (0.07 to 0.29) | 2.86 (2.00 to 4.07) |
| 7vPnC serotype 6B | 3.97 (2.78 to 5.67) | 22.62 (14.56 to 35.16) |
| 7vPnC serotype 9V | 1.69 (1.20 to 2.38) | 4.70 (3.49 to 6.33) |
| 7vPnC serotype 14 | 0.79 (0.43 to 1.43) | 18.50 (10.10 to 33.90) |
| 7vPnC serotype 18C | 0.72 (0.46 to 1.13) | 9.79 (6.43 to 14.90) |
| 7vPnC serotype 19F | 2.01 (1.32 to 3.05) | 18.02 (11.56 to 28.08) |
| 7vPnC serotype 23F | 2.31 (1.70 to 3.14) | 20.80 (13.07 to 33.08) |
| Additional serotype 1 | 0.70 (0.43 to 1.15) | 5.30 (3.40 to 8.26) |
| Additional serotype 3 | 1.16 (0.73 to 1.86) | 1.81 (1.25 to 2.62) |
| Additional serotype 5 | 3.83 (2.77 to 5.31) | 7.39 (4.98 to 10.96) |
| Additional serotype 6A | 3.82 (2.79 to 5.23) | 17.05 (10.82 to 26.87) |
| Additional serotype 7F | 1.12 (0.73 to 1.72) | 5.94 (4.08 to 8.65) |
| Additional serotype 19A | 6.18 (4.57 to 8.35) | 20.17 (15.28 to 26.63) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | 7vPnC / 13vPnC Prevaccination Visit 1 | 7vPnC / 13vPnC Postvaccination Visit 4 |
|---|---|---|
| 7vPnC serotype 4 | 0.20 (0.12 to 0.33) | 3.21 (2.10 to 4.90) |
| 7vPnC serotype 6B | 5.89 (4.61 to 7.51) | 29.46 (20.74 to 41.86) |
| 7vPnC serotype 9V | 1.54 (1.19 to 2.00) | 5.96 (4.57 to 7.76) |
| 7vPnC serotype 14 | 0.58 (0.39 to 0.86) | 10.25 (6.85 to 15.33) |
| 7vPnC serotype 18C | 0.75 (0.48 to 1.18) | 3.17 (2.26 to 4.42) |
| 7vPnC serotype 19F | 2.94 (2.08 to 4.15) | 7.46 (5.43 to 10.25) |
| 7vPnC serotype 23F | 2.51 (1.92 to 3.27) | 10.56 (7.69 to 14.51) |
| Additional serotype 1 | 1.04 (0.71 to 1.54) | 4.42 (2.93 to 6.67) |
| Additional serotype 3 | 1.30 (0.83 to 2.04) | 2.12 (1.54 to 2.92) |
| Additional serotype 5 | 3.24 (2.45 to 4.27) | 5.40 (4.08 to 7.15) |
| Additional serotype 6A | 3.78 (2.85 to 5.03) | 13.60 (9.01 to 20.53) |
| Additional serotype 7F | 1.38 (0.93 to 2.05) | 4.70 (3.26 to 6.78) |
| Additional serotype 19A | 7.05 (5.52 to 8.99) | 13.40 (10.30 to 17.42) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | MnCC / 13vPnC Prevaccination Visit 1 | MnCC / 13vPnC Postvaccination Visit 4 |
|---|---|---|
| 7vPnC serotype 4 | 0.15 (0.07 to 0.29) | 1.21 (0.70 to 2.11) |
| 7vPnC serotype 6B | 3.97 (2.78 to 5.67) | 9.42 (6.23 to 14.24) |
| 7vPnC serotype 9V | 1.69 (1.20 to 2.38) | 3.41 (2.51 to 4.65) |
| 7vPnC serotype 14 | 0.79 (0.43 to 1.43) | 5.22 (2.76 to 9.86) |
| 7vPnC serotype 18C | 0.72 (0.46 to 1.13) | 3.53 (2.16 to 5.76) |
| 7vPnC serotype 19F | 2.01 (1.32 to 3.05) | 5.47 (3.51 to 8.54) |
| 7vPnC serotype 23F | 2.31 (1.70 to 3.14) | 6.51 (4.24 to 10.01) |
| Additional serotype 1 | 0.70 (0.43 to 1.15) | 2.65 (1.75 to 4.00) |
| Additional serotype 3 | 1.11 (0.67 to 1.82) | 1.46 (0.97 to 2.20) |
| Additional serotype 5 | 3.83 (2.77 to 5.31) | 5.00 (3.49 to 7.15) |
| Additional serotype 6A | 3.82 (2.79 to 5.23) | 7.79 (5.17 to 11.72) |
| Additional serotype 7F | 1.12 (0.73 to 1.72) | 3.21 (2.25 to 4.59) |
| Additional serotype 19A | 6.18 (4.57 to 8.35) | 12.03 (8.83 to 16.39) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | 7vPnC / 13vPnC Prevaccination Visit 1 | 7vPnC / 13vPnC Postvaccination Visit 5 |
|---|---|---|
| 7vPnC serotype 4 | 22 (6.3 to 80.7) | 4535 (2836.5 to 7251.3) |
| 7vPnC serotype 6B | 1024 (488.4 to 2148.4) | 11939 (8748.1 to 16293.9) |
| 7vPnC serotype 9V | 43 (13.4 to 137.3) | 6709 (5097.5 to 8829.4) |
| 7vPnC serotype 14 | 159 (63.7 to 396.0) | 5946 (4361.1 to 8107.6) |
| 7vPnC serotype 18C | 54 (19.5 to 149.5) | 5067 (3375.1 to 7607.2) |
| 7vPnC serotype 19F | 33 (15.1 to 73.3) | 1623 (995.2 to 2647.9) |
| 7vPnC serotype 23F | 87 (34.1 to 223.4) | 2799 (2048.5 to 3823.2) |
| Additional serotype 1 | 6 (4.3 to 7.4) | 440 (301.8 to 641.2) |
| Additional serotype 3 | 11 (6.9 to 16.6) | 111 (87.1 to 141.1) |
| Additional serotype 5 | 4 (3.6 to 5.6) | 277 (145.2 to 526.4) |
| Additional serotype 6A | 17 (7.1 to 39.7) | 9029 (6255.0 to 13034.0) |
| Additional serotype 7F | 60 (17.7 to 205.3) | 7036 (4886.0 to 10131.8) |
| Additional serotype 19A | 76 (36.7 to 157.5) | 1869 (1099.8 to 3177.3) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | MnCC / 13vPnC Prevaccination Visit 1 | MnCC / 13vPnC Postvaccination Visit 5 |
|---|---|---|
| 7vPnC serotype 4 | 28 (4.5 to 174.3) | 4704 (2958.0 to 7481.1) |
| 7vPnC serotype 6B | 288 (74.8 to 1106.9) | 11607 (7762.6 to 17354.1) |
| 7vPnC serotype 9V | 120 (37.9 to 382.8) | 7457 (5702.3 to 9751.9) |
| 7vPnC serotype 14 | 262 (98.1 to 700.5) | 7006 (4997.7 to 9822.1) |
| 7vPnC serotype 18C | 25 (8.4 to 75.7) | 5736 (4141.4 to 7943.8) |
| 7vPnC serotype 19F | 23 (10.5 to 50.6) | 2696 (1831.0 to 3968.5) |
| 7vPnC serotype 23F | 11 (5.0 to 23.5) | 5197 (3599.2 to 7503.1) |
| Additional serotype 1 | 5 (4.0 to 6.6) | 341 (221.9 to 524.9) |
| Additional serotype 3 | 11 (7.0 to 18.2) | 98 (75.2 to 126.9) |
| Additional serotype 5 | 4 (3.7 to 5.0) | 336 (175.4 to 642.2) |
| Additional serotype 6A | 24 (8.9 to 64.2) | 10488 (7460.6 to 14744.7) |
| Additional serotype 7F | 76 (21.1 to 275.2) | 6098 (4392.9 to 8464.9) |
| Additional serotype 19A | 39 (19.9 to 78.1) | 2424 (1696.6 to 3462.4) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | 7vPnC / 13vPnC Prevaccination Visit 1 | 7vPnC / 13vPnC Postvaccination Visit 4 |
|---|---|---|
| 7vPnC serotype 4 | 19 (6.0 to 62.8) | 5449 (3118.6 to 9519.8) |
| 7vPnC serotype 6B | 1034 (505.1 to 2116.9) | 7885 (5792.0 to 10734.0) |
| 7vPnC serotype 9V | 43 (13.4 to 137.3) | 6497 (4357.4 to 9687.5) |
| 7vPnC serotype 14 | 148 (58.2 to 375.7) | 3497 (2440.8 to 5009.1) |
| 7vPnC serotype 18C | 58 (20.6 to 163.8) | 5922 (3784.0 to 9268.9) |
| 7vPnC serotype 19F | 40 (17.4 to 91.6) | 1243 (620.6 to 2489.8) |
| 7vPnC serotype 23F | 79 (31.4 to 201.3) | 1487 (884.7 to 2499.5) |
| Additional serotype 1 | 6 (4.3 to 7.6) | 367 (228.8 to 587.3) |
| Additional serotype 3 | 11 (6.9 to 16.6) | 119 (82.1 to 172.0) |
| Additional serotype 5 | 4 (3.6 to 5.6) | 185 (100.9 to 337.5) |
| Additional serotype 6A | 17 (7.1 to 39.7) | 8072 (5195.8 to 12538.8) |
| Additional serotype 7F | 60 (17.7 to 205.3) | 4601 (2998.3 to 7060.6) |
| Additional serotype 19A | 76 (36.7 to 157.5) | 1345 (767.4 to 2357.7) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | MnCC / 13vPnC Prevaccination Visit 1 | MnCC / 13vPnC Postvaccination Visit 4 |
|---|---|---|
| 7vPnC serotype 4 | 40 (6.3 to 254.0) | 6782 (3687.6 to 12471.3) |
| 7vPnC serotype 6B | 405 (103.5 to 1584.7) | 7195 (4585.5 to 11289.8) |
| 7vPnC serotype 9V | 116 (36.8 to 364.9) | 7855 (5532.9 to 11152.1) |
| 7vPnC serotype 14 | 280 (103.1 to 760.7) | 6209 (4253.9 to 9063.3) |
| 7vPnC serotype 18C | 25 (8.4 to 75.7) | 5193 (3658.1 to 7372.3) |
| 7vPnC serotype 19F | 20 (9.4 to 44.7) | 1855 (1055.8 to 3258.2) |
| 7vPnC serotype 23F | 11 (5.0 to 23.5) | 991 (501.3 to 1959.3) |
| Additional serotype 1 | 5 (4.0 to 6.5) | 385 (249.4 to 595.6) |
| Additional serotype 3 | 12 (7.2 to 19.0) | 101 (72.2 to 141.7) |
| Additional serotype 5 | 4 (3.7 to 5.0) | 258 (132.3 to 503.4) |
| Additional serotype 6A | 23 (8.7 to 59.1) | 6107 (4149.7 to 8987.5) |
| Additional serotype 7F | 95 (24.7 to 363.8) | 3577 (1774.8 to 7208.2) |
| Additional serotype 19A | 39 (19.9 to 78.1) | 1763 (1220.1 to 2547.6) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 5.73 (4.21 to 7.81) | 2.92 (2.22 to 3.83) |
| 7vPnC serotype 6B | 66.72 (50.19 to 88.70) | 22.62 (14.56 to 35.16) |
| 7vPnC serotype 9V | 8.72 (6.68 to 11.40) | 4.70 (3.49 to 6.33) |
| 7vPnC serotype 14 | 41.45 (27.72 to 61.97) | 18.50 (10.10 to 33.90) |
| 7vPnC serotype 18C | 5.72 (4.18 to 7.82) | 9.04 (5.98 to 13.68) |
| 7vPnC serotype 19F | 14.17 (9.54 to 21.07) | 15.80 (10.00 to 24.96) |
| 7vPnC serotype 23F | 17.20 (12.44 to 23.77) | 20.80 (13.07 to 33.08) |
| Additional serotype 1 | 9.55 (6.46 to 14.13) | 5.63 (3.67 to 8.64) |
| Additional serotype 3 | 2.13 (1.58 to 2.87) | 1.71 (1.20 to 2.44) |
| Additional serotype 5 | 6.80 (4.75 to 9.74) | 7.52 (5.12 to 11.04) |
| Additional serotype 6A | 29.11 (19.04 to 44.50) | 16.08 (10.18 to 25.40) |
| Additional serotype 7F | 9.92 (7.03 to 14.01) | 5.75 (3.98 to 8.33) |
| Additional serotype 19A | 21.29 (14.90 to 30.43) | 20.17 (15.28 to 26.63) |
Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Mcg/mL | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 3.00 (2.07 to 4.35) | 1.37 (0.90 to 2.10) |
| 7vPnC serotype 6B | 29.46 (20.74 to 41.86) | 9.42 (6.23 to 14.24) |
| 7vPnC serotype 9V | 5.75 (4.40 to 7.51) | 3.41 (2.51 to 4.65) |
| 7vPnC serotype 14 | 10.25 (6.85 to 15.33) | 5.22 (2.76 to 9.86) |
| 7vPnC serotype 18C | 3.09 (2.22 to 4.29) | 3.45 (2.16 to 5.52) |
| 7vPnC serotype 19F | 7.66 (5.66 to 10.36) | 4.85 (3.09 to 7.62) |
| 7vPnC serotype 23F | 10.56 (7.69 to 14.51) | 6.51 (4.24 to 10.01) |
| Additional serotype 1 | 3.98 (2.82 to 5.62) | 2.83 (1.86 to 4.32) |
| Additional serotype 3 | 2.02 (1.48 to 2.76) | 1.40 (0.95 to 2.06) |
| Additional serotype 5 | 5.40 (4.08 to 7.15) | 5.12 (3.60 to 7.28) |
| Additional serotype 6A | 13.60 (9.01 to 20.53) | 7.25 (4.75 to 11.06) |
| Additional serotype 7F | 4.70 (3.26 to 6.78) | 3.17 (2.24 to 4.48) |
| Additional serotype 19A | 13.40 (10.30 to 17.42) | 12.03 (8.83 to 16.39) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 4626 (3322.5 to 6441.2) | 6065 (4590.9 to 8012.5) |
| 7vPnC serotype 6B | 11451 (8290.4 to 15817.9) | 10380 (7515.2 to 14336.9) |
| 7vPnC serotype 9V | 6346 (5152.2 to 7817.5) | 7555 (5916.7 to 9646.8) |
| 7vPnC serotype 14 | 5898 (4481.0 to 7762.1) | 7031 (5195.6 to 9515.5) |
| 7vPnC serotype 18C | 5090 (3428.4 to 7557.7) | 6005 (4389.3 to 8214.6) |
| 7vPnC serotype 19F | 1623 (995.2 to 2647.9) | 2696 (1831.0 to 3968.5) |
| 7vPnC serotype 23F | 2752 (2074.6 to 3651.3) | 4841 (3574.5 to 6555.1) |
| Additional serotype 1 | 449 (312.8 to 643.2) | 347 (228.3 to 527.4) |
| Additional serotype 3 | 113 (89.2 to 143.5) | 99 (77.0 to 126.3) |
| Additional serotype 5 | 296 (158.8 to 549.9) | 336 (175.4 to 642.2) |
| Additional serotype 6A | 9458 (6674.2 to 13404.0) | 10842 (7904.9 to 14870.9) |
| Additional serotype 7F | 6740 (4933.2 to 9207.7) | 6050 (4515.0 to 8106.7) |
| Additional serotype 19A | 2120 (1308.0 to 3435.3) | 2340 (1667.0 to 3285.4) |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| Titer | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 5567 (3202.5 to 9678.7) | 8339 (6154.1 to 11299.5) |
| 7vPnC serotype 6B | 8082 (5743.5 to 11372.6) | 6450 (4477.8 to 9290.2) |
| 7vPnC serotype 9V | 6865 (4826.7 to 9763.7) | 7806 (5491.4 to 11095.6) |
| 7vPnC serotype 14 | 3596 (2613.0 to 4948.5) | 5994 (4246.9 to 8460.1) |
| 7vPnC serotype 18C | 5833 (3770.5 to 9023.7) | 5266 (3779.3 to 7338.4) |
| 7vPnC serotype 19F | 1243 (620.6 to 2489.8) | 1855 (1055.8 to 3258.2) |
| 7vPnC serotype 23F | 1575 (987.7 to 2511.7) | 1141 (655.1 to 1986.8) |
| Additional serotype 1 | 379 (241.8 to 594.9) | 393 (257.2 to 600.3) |
| Additional serotype 3 | 117 (81.3 to 167.5) | 104 (75.4 to 143.4) |
| Additional serotype 5 | 200 (111.2 to 358.6) | 258 (132.3 to 503.4) |
| Additional serotype 6A | 8534 (5631.9 to 12931.6) | 6199 (4357.6 to 8818.6) |
| Additional serotype 7F | 4750 (3291.8 to 6852.9) | 3760 (2106.7 to 6709.5) |
| Additional serotype 19A | 1504 (911.2 to 2484.1) | 1761 (1242.8 to 2496.0) |
Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (\> 7.0 cm). Participants may be represented in \>1 category.
| percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| Tenderness: Any | 92.1 | 86.1 |
| Tenderness: Significant | 10.5 | 19.4 |
| Swelling: Any | 10.5 | 5.6 |
| Swelling: Mild | 2.6 | 2.8 |
| Swelling: Moderate | 10.5 | 2.8 |
| Redness: Any | 5.3 | 5.6 |
| Redness: Mild | 0.0 | 2.8 |
| Redness: Moderate | 5.3 | 2.8 |
Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), \>39 but ≤40 degrees C (moderate), or \>40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).
| percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C | 2.9 | 0.0 |
| Decreased appetite | 7.9 | 16.7 |
| Decreased appetite: Mild | 7.9 | 11.1 |
| Decreased appetite: Moderate | 2.6 | 8.3 |
| Irritability | 18.4 | 13.9 |
| Irritability: Mild | 13.2 | 11.1 |
| Irritability: Moderate | 5.3 | 5.6 |
| Increased sleep | 26.3 | 33.3 |
| Increased sleep: Mild | 15.8 | 25.0 |
| Increased sleep: Moderate | 13.2 | 13.9 |
| Increased sleep: Severe | 2.6 | 0.0 |
| Decreased sleep | 7.9 | 11.1 |
| Decreased sleep: Mild | 5.3 | 8.3 |
| Decreased sleep: Moderate | 2.6 | 2.8 |
| Rash | 5.3 | 0.0 |
| Rash: Mild | 5.3 | 0.0 |
Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 100.0 (90.3 to 100.0) | 100.0 (89.1 to 100.0) |
| 7vPnC serotype 6B | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 14 | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 18C | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 19F | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 23F | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 1 | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| Additional serotype 3 | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 5 | 97.4 (86.2 to 99.9) | 94.3 (80.8 to 99.3) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| Additional serotype 7F | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 19A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.
| observed percentage of participants | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| 7vPnC serotype 4 | 97.4 (86.2 to 99.9) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 6B | 100.0 (90.7 to 100.0) | 100.0 (89.4 to 100.0) |
| 7vPnC serotype 9V | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 14 | 100.0 (90.5 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 18C | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| 7vPnC serotype 19F | 100.0 (90.0 to 100.0) | 100.0 (89.7 to 100.0) |
| 7vPnC serotype 23F | 97.3 (85.8 to 99.9) | 94.3 (80.8 to 99.3) |
| Additional serotype 1 | 100.0 (90.5 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 3 | 100.0 (90.7 to 100.0) | 100.0 (89.7 to 100.0) |
| Additional serotype 5 | 97.4 (86.2 to 99.9) | 94.1 (80.3 to 99.3) |
| Additional serotype 6A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
| Additional serotype 7F | 100.0 (90.5 to 100.0) | 100.0 (89.4 to 100.0) |
| Additional serotype 19A | 100.0 (90.7 to 100.0) | 100.0 (90.0 to 100.0) |
Collected over Baseline up to Day 4 after vaccination for local reactions and systemic events or up to Day 194 (Visit 6 / Days 166 to 194 Follow-up Telephone Visit to assess AEs). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 7vPnC / 13vPnC | — | 0/38 (0%) | 38/38 (100%) |
| MnCC / 13vPnC | — | 0/36 (0%) | 36/36 (100%) |
| Event | 7vPnC / 13vPnC | MnCC / 13vPnC |
|---|---|---|
| Tenderness: AnySkin and subcutaneous tissue disorders | 35/38 | 31/36 |
| Increased sleepGeneral disorders | 10/38 | 12/36 |
| Increased sleep: MildGeneral disorders | 6/38 | 9/36 |
| Tenderness: SignificantSkin and subcutaneous tissue disorders | 4/38 | 7/36 |
| IrritabilityGeneral disorders | 7/38 | 5/36 |
| Decreased appetiteGeneral disorders | 3/38 | 6/36 |
| Increased sleep: ModerateGeneral disorders | 5/38 | 5/36 |
| Irritability: MildGeneral disorders | 5/38 | 4/36 |
| Injection site painGeneral disorders | 4/38 | 4/36 |
| Decreased appetite: MildGeneral disorders | 3/38 | 4/36 |
| Age Continuous(years) | 7vPnC / 13vPnC | MnCC / 13vPnC | Total |
|---|---|---|---|
| Mean | 12.6 ± 1.1 | 13.1 ± 0.9 | 12.8 ± 1.0 |
| Sex: Female, Male(Participants) | 7vPnC / 13vPnC | MnCC / 13vPnC | Total |
|---|---|---|---|
| Female | 15 | 16 | 31 |
| Male | 23 | 21 | 44 |
The record gives a start of Jan 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine